- Home
- ELLO vs DMAC Comparison
ELLO vs DMAC Comparison
Compare ELLO & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELLO
- DMAC
- Stock Information
- Founded
- ELLO 1987
- DMAC 2000
- Country
- ELLO Israel
- DMAC United States
- Employees
- ELLO N/A
- DMAC N/A
- Industry
- ELLO Electric Utilities: Central
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- ELLO Utilities
- DMAC Health Care
- Exchange
- ELLO Nasdaq
- DMAC Nasdaq
- Market Cap
- ELLO 208.2M
- DMAC 178.0M
- IPO Year
- ELLO 1995
- DMAC N/A
- Fundamental
- Price
- ELLO $17.00
- DMAC $4.14
- Analyst Decision
- ELLO
- DMAC Strong Buy
- Analyst Count
- ELLO 0
- DMAC 4
- Target Price
- ELLO N/A
- DMAC $10.75
- AVG Volume (30 Days)
- ELLO 11.7K
- DMAC 405.5K
- Earning Date
- ELLO 06-30-2025
- DMAC 08-06-2025
- Dividend Yield
- ELLO N/A
- DMAC N/A
- EPS Growth
- ELLO N/A
- DMAC N/A
- EPS
- ELLO 0.43
- DMAC N/A
- Revenue
- ELLO $44,405,534.00
- DMAC N/A
- Revenue This Year
- ELLO N/A
- DMAC N/A
- Revenue Next Year
- ELLO N/A
- DMAC N/A
- P/E Ratio
- ELLO $43.83
- DMAC N/A
- Revenue Growth
- ELLO N/A
- DMAC N/A
- 52 Week Low
- ELLO $11.30
- DMAC $3.19
- 52 Week High
- ELLO $20.81
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- ELLO 55.71
- DMAC 52.42
- Support Level
- ELLO $15.40
- DMAC $3.65
- Resistance Level
- ELLO $17.50
- DMAC $4.42
- Average True Range (ATR)
- ELLO 0.59
- DMAC 0.31
- MACD
- ELLO -0.10
- DMAC 0.04
- Stochastic Oscillator
- ELLO 50.96
- DMAC 51.60
About ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is focused on the utility sector. It is an Israeli public company, which focuses its business in the energy and infrastructure sectors. The company's operating segment includes Photovoltaic power plants (PV Plants); Dorad Energy Ltd. (Dorad); Groen Gas Goor B.V. and a Pumped storage hydro power plant (Manara). It generates maximum revenue from the Dorad segment. Geographically, it derives a majority of its revenue from Spain.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.